bioAffinity Technologies, Inc. BIAF
Biotechnology: Commercial Physical & Biological Resarch · IPO 2022 · data as of November 13, 2026
bioAffinity Technologies, Inc. (BIAF) is a healthcare company listed in the US with a market value of about $4M. In the twelve months to September 30, 2026 it had revenue of $6M and net income of -$15M, a net margin of -278.9%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -118%.
About bioAffinity Technologies
bioAffinity Technologies is listed in the US and classified in biotechnology: commercial physical & biological resarch, IPO year 2022. Revenue went from $7M in 2022 to $6M in 2025, a decline of about 3.7% a year. It was profitable in 0 of the last 5 years in our data. Its share count rose by 1048% over three years (dilution for shareholders). It spends 22% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $6M | $6M | $9M | $8M | $7M | — |
| Net income | -$15M | -$15M | -$9M | -$8M | -$8M | -$6M |
| Free cash flow | -$13M | -$9M | -$7M | -$6M | -$4M | — |
| EPS (diluted) | $-8.95 | $-8.66 | $-22.50 | $-27.30 | $-54.30 | $-70.80 |
| Net margin | -278.9% | -242.0% | -96.6% | -100.5% | -118.2% | — |
| ROIC | — | -107.5% | -216.7% | -120.4% | -28.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does bioAffinity Technologies pay a dividend?
Not currently.
Is bioAffinity Technologies a good stock to buy?
We do not give buy or sell advice. bioAffinity Technologies scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.